Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II, Open Label, Multi-center, Multi-arm Study of Ceritinib in Patients With Advanced Solid Tumors and Hematological Malignancies Characterized by Genetic Abnormalities of Anaplastic Lymphoma Kinase (ALK)

Next Previous
Search
Trial Profile

A Phase II, Open Label, Multi-center, Multi-arm Study of Ceritinib in Patients With Advanced Solid Tumors and Hematological Malignancies Characterized by Genetic Abnormalities of Anaplastic Lymphoma Kinase (ALK)

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 09 Feb 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ceritinib (Primary)
  • Indications Adenocarcinoma; Anaplastic large cell lymphoma; Colon cancer; Gastric cancer; Glioblastoma; Haematological malignancies; Sarcoma; Soft tissue sarcoma; Solid tumours
  • Focus Proof of concept; Therapeutic Use
  • Acronyms ASCEND-10
  • Sponsors Novartis; Novartis Pharmaceuticals

    • Most Recent Events

    • 31 May 2020 Results assessing ceritinib efficacy and safety in pts with advanced ALK+ non-lung solid tumors and hematological malignancies, presented at the 56th Annual Meeting of the American Society of Clinical Oncology.
    • 17 Dec 2019 Status changed from completed to discontinued.
    • 01 Dec 2018 Status changed from recruiting to completed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top